Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92732 | 0.88 | POLB (0.52) | POLBAPOBEC3AAPOBEC3GKDM4EL3MBTL1 | |
| SCHEMBL15871091 | 0.78 | CYP2C19 (0.46) | POLBAPOBEC3AAPOBEC3GKDM4EL3MBTL1 | |
| SCHEMBL5843057 | 0.78 | MAPT (0.47) | KDM4EL3MBTL1ALDH1A1HSD17B10MAPT | |
| SCHEMBL15871122 | 0.77 | POLB (0.44) | POLBAPOBEC3AAPOBEC3GKDM4EL3MBTL1 | |
| SCHEMBL4741738 | 0.77 | POLB (0.44) | POLBAPOBEC3AAPOBEC3GKDM4EL3MBTL1 | |
| SCHEMBL3894942 | 0.77 | TDP1 (0.52) | POLBAPOBEC3AAPOBEC3GKDM4EL3MBTL1 | |
| SCHEMBL6612375 | 0.77 | POLB (0.37) | POLBAPOBEC3AAPOBEC3GKDM4EL3MBTL1 | |
| SCHEMBL2184301 | 0.75 | SLC16A3 (0.32) | ALDH1A1MEN1KMT2A | |
| SCHEMBL8721633 | 0.74 | ALDH1A1 (0.35) | POLBAPOBEC3AAPOBEC3GKDM4EL3MBTL1 | |
| SCHEMBL8657449 | 0.74 | HTR2A (0.31) | KDM4EALDH1A1KMT2AMAPTHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100534990-C | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | claimed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | claimed |
| CN-1610678-A | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS LTD (CH) | 2005-04-27 | — | — | CN | claimed |
| EP-1463724-A1 | PYRROLIDONE CARBOXAMIDES | Actelion Pharmaceuticals Ltd. (CH) | 2004-10-06 | — | — | EP | claimed |
| WO-2003059905-A1 | PYRROLIDONE CARBOXAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-07-24 | — | — | WO | claimed |
| CN-100534990-C | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | disclosed |
| US-7067549-B2 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | disclosed |
| CN-1610678-A | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS LTD (CH) | 2005-04-27 | — | — | CN | disclosed |
| EP-1463724-A1 | PYRROLIDONE CARBOXAMIDES | Actelion Pharmaceuticals Ltd. (CH) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003059905-A1 | PYRROLIDONE CARBOXAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | NPY1R, NPY5R, NPY2R | POLB 4023/4885APOBEC3A 4599/4885APOBEC3G 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.